Digital toolkit for assessment
OtherThe pilot study uses a digital assessment and intervention toolkit. The person with dementia and caregivers may choose from the digital interventions offered in the toolbox without any mandatory conditions.
NCT Number: NCT06289322
The pilot study will develop and test a standardized assessment toolkit that will provide conclusive information with a tolerable burden for cognitively impaired patients with dementia.
Trial opening soon.
Get NotifiedAll sexes
Interventional
Not applicable
The clinical study is part of an EU-funded project on the use of artificial intelligence for patients with dementia. This study will test a digital toolkit fo assessment and monitoring of patients with mild or moderate dementia and pilot-test this toolkit for feasibility and acceptability.
Patients with mild to moderate dementia will be recruited for the pilot study in the six participating countries. The study population includes all types of dementia without stratification, as the aim of the study is to construct a digital assessment and intervention toolkit for clinical practice in any patient with cognitive impairment from any type of dementia.
Even though the final assessment and intervention toolkit could also be useful for patients with advanced dementia and more severe cognitive impairment, the pilot study will recruit only patients with mild or moderate dementia, who will still be able to provide informed consent, and who will be able to self-assess at least minimum patient-related outcome or patient-related experience measures to validate the behavioural and observational scales and biomarkers used in the toolkit.
Patients with dementia treated in the participating study centers will be screened for inclusion criteria and, if suitable will be invited to participate. The study will be performed for seven days, with optional extension to 30 days according to patients' preferences.
Patients with baseline data and at least one intervention performed from the digital toolkit and data completed before and after that intervention will be included in the evaluation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The pilot study uses a digital assessment and intervention toolkit. The person with dementia and caregivers may choose from the digital interventions offered in the toolbox without any mandatory conditions.
Time frame: 7 days
Patient feedback on feasibility, usefulness and burden of toolkit
Time frame: 7 days
Comparison of toolkit assessments of pain and distress (including facial emotional recognition from weekly diary recordings) and PROM/PREM.
Time frame: 7 days
Comparison of before/after assessments of interventions to alleviate pain or distress using the digital toolkit.
Time frame: Baseline, once per intervention week (at the end of the week)
Exploration of specific linguistics and behavioural markers and their correlation with clinical assess-ment tools' scores.
Time frame: At the end of intervention
PROM/PREM completion rates, user engagement patterns, and dropout analysis.
Time frame: At the end of intervention
Feedback on the diary interface and user experience that could inform future iterations.
Contact information is provided by the study sponsor or research team.
Holger Brunsch, Dr.
CONTACT
Lukas Radbruch, MD
CONTACT
University of Bonn
Other
AI4HOPE - Artificial Intelligence Based Health, Optimism, Purpose and Endurance in Palliative Care for Dementia: Pilot Study 1 Digital Toolkit Assessment
Acronym: AI4HOPE1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07730983
Brain Diseases, Central Nervous System Diseases
Lamotte-Beuvron, France
View Trial DetailsNCT07718906
Brain Diseases, Central Nervous System Diseases
Morgantown, West Virginia, United States
View Trial DetailsNCT07488195
Brain Diseases, Central Nervous System Diseases
Rochester, Minnesota, United States
View Trial DetailsNCT07216950
Brain Diseases, Caregiving
Cleveland, Ohio, United States
View Trial Details